G31.81 Alpers disease

Name of the Condition

• Alpers disease

Summary

Alpers disease is a rare, progressive neurodegenerative disorder that primarily affects the brain and liver. It is characterized by the degeneration of gray matter in the cerebrum, leading to severe neurological impairment. The condition typically manifests in infancy or early childhood and follows a relentless course, with symptoms worsening over time.

Causes

Alpers disease is caused by mutations in the POLG gene, which provides instructions for producing a protein essential for mitochondrial DNA replication. These genetic mutations disrupt mitochondrial function, leading to energy deficits in cells, particularly in the brain and liver. The condition is inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the mutated gene for a child to be affected.

Risk Factors

• Genetic inheritance: Having parents who are carriers of the POLG gene mutation.
• Age of onset: Most cases occur in infancy or early childhood, though rare adult-onset variants exist.
• Family history: A history of neurodegenerative disorders in the family may increase risk.

Symptoms

• Seizures, often resistant to treatment
• Developmental regression, including loss of motor skills and speech
• Liver dysfunction, such as jaundice or elevated liver enzymes
• Progressive cerebral atrophy, leading to cognitive decline
• Muscle weakness and spasticity
• Vision problems, including optic atrophy

Diagnosis

Diagnosis is based on clinical presentation, genetic testing for POLG mutations, and imaging studies. MRI of the brain may reveal cortical atrophy and white matter changes. Laboratory tests, including liver function tests and metabolic panels, help assess organ involvement. In some cases, a liver biopsy may be performed to confirm mitochondrial dysfunction.

Treatment Options

Treatment focuses on managing symptoms and supporting organ function. Antiepileptic medications are used to control seizures, though they may be ineffective in advanced cases. Nutritional support and liver monitoring are critical. Physical and occupational therapy can help maintain mobility and function. No cure exists, and management is primarily palliative.

Prognosis and Follow-Up

Alpers disease has a poor prognosis, with most affected individuals surviving only a few years after symptom onset. Regular follow-up with neurologists and hepatologists is essential to monitor neurological and liver status. Supportive care, including seizure management and nutritional support, is crucial for quality of life.

Complications

• Refractory seizures, which may worsen with time
• Liver failure, a common cause of mortality
• Progressive neurological deterioration, leading to loss of motor and cognitive function
• Respiratory complications due to muscle weakness

Lifestyle & Prevention

• Genetic counseling for families with a history of POLG mutations.
• Avoiding known triggers, such as certain medications that may exacerbate liver or mitochondrial dysfunction.
• Maintaining a balanced diet to support overall health, though no specific dietary interventions can prevent disease progression.

When to Seek Professional Help

Seek immediate medical attention if seizures occur, especially if they are new or worsening, or if signs of liver dysfunction (e.g., jaundice, abdominal pain) are present. Early consultation with a neurologist or geneticist is recommended for suspected cases.

Tips for Medical Coders

When coding for Alpers disease, use ICD-10-CM code G31.81. Ensure documentation supports the diagnosis, including clinical findings, genetic testing results, and any associated complications (e.g., seizures, liver disease). Code accurately to reflect the underlying mitochondrial disorder and its systemic manifestations.